Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    2 September 2024

    Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568

    Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. - formerly known as Sosei Group or Sosei Heptares – announces it will receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults wi...

    6 September 2024

    ARU vision research shortlisted for national awards

    Anglia Ruskin University nominated in two categories by Times Higher Education.

    6 September 2024

    Qkine expands senior leadership

    Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer. ...

    9 September 2024

    CMR Surgical strengthens senior team

    CMR Surgical, the global surgical robotics business, announces the appointment of Markus Bauman as Chief Legal & Business Affairs Officer, joining the Company’s executive leadership team. ...

    9 September 2024


    Natural probiotic discovered in UK newborns' microbiomes

    Newborn babies have one of three pioneer bacteria in their gut shortly after birth, one of which could be used to develop new personalised infant therapeutic probiotics, researchers show. ...

    10 September 2024

    o2h technology announces the launch of the third edition of the Tech Kickstarter Competition

    Cambridge, UK: o2h technology, a business vertical of the o2h group, is thrilled to announce the launch of the third edition of its Tech Kickstarter Competition. This initiative is designed to support innovative seed and early stage companies by helping them meet their MVP, ...

    10 September 2024

    Common diabetes drug slows growth of normal cells carrying cancer mutation

    A common diabetes medication, metformin, slows the growth of precancerous cells in the oesophagus while some metabolic conditions accelerate it, suggests a new study. ...

    11 September 2024

    Team’s hip replacement surgery invention is set to be world first

    Technology which is the first of its kind in the world and could transform the future of hip replacement surgery is being pioneered by a team of experts in Cambridge. ...

    13 September 2024

    Owlstone Medical celebrates success at SME Cambridgeshire Business Awards

    It was a double success as the Owlstone Medical team scooped two awards. The company won Website of the Year for its OMED Health website and silver for Employer of the Year. ...

    13 September 2024

    MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 51
    • Page 52
    • Current page 53
    • Page 54
    • Page 55
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS